DiaMedica Therapeutics Q1 net loss widens to $10.0 million; cash falls to $51.3 million
DiaMedica reported a first-quarter 2026 net loss of $10.0 million, up from $7.7 million a year earlier, as research and development spending rose on its ReMEDy2 stroke trial and preeclampsia program. Cash and short-term investments fell to $51.3 million from $59.9 million at December 31, 2025, and the company says that balance will fund planned studies through 2027, which matters to shareholders because the company reports no revenue and depends on outside funding.
Key points
- Net loss was $10.0 million for the quarter ended March 31, 2026, compared with $7.7 million a year earlier.
- Research and development expenses rose to $8.0 million from $5.7 million, driven mainly by the ReMEDy2 trial and related expansion.
- Cash and short-term investments were $51.3 million at March 31, 2026, versus $59.9 million at December 31, 2025, and are expected to last through 2027.
- Net loss per share was $0.19, compared with $0.18 a year earlier, on 53,793,490 weighted average shares.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.